Status:
RECRUITING
A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Conditions:
C-KIT Mutation
Eligibility:
All Genders
14+ years
Brief Summary
C-Kit is involved in an essential pathway of disease occurrence and is closely related to the poor prognosis of patients. However, the clinical significance of c-Kit mutation as molecular MRD monitori...
Eligibility Criteria
Inclusion
- Patients who meet the diagnostic criteria(WHO 2016 criteria) of AML and have c-Kit D816 mutation. And receive treatment.
Exclusion
- Patients with other factors which were considered unsuitable to participate in the study by the investigators
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06116318
Start Date
November 1 2023
End Date
November 1 2026
Last Update
May 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Hematology & Blood Diseases Hospital
Tianjin, China